Skip NavigationSkip to Content
Return Return to Search Results

Anticancer medicines in development: assessment of bioactivity profiles within the National Cancer Institute anticancer screening data

  1. Author:
    Covell, D. G.
    Huang, R. L.
    Wallqvist, A.

  2. Author Address

    NCI, Frederick Dev Therapeut Program, Comp Technol Lab, Screening Technol Branch, Frederick, MD 21702 USA. Sci Applicat Int Corp Frederick Inc, Comp Technol Lab, NCI, Frederick, MD USA.;Covell, DG, NCI, Frederick Dev Therapeut Program, Comp Technol Lab, Screening Technol Branch, Frederick, MD 21702 USA.;covell@ncifcrf.gov
    1. Year: 2007
    2. Date: Aug
  2. Journal: Molecular Cancer Therapeutics
    1. 6
    2. 8
    3. Pages: 2261-2270
  4. Type of Article: Article
  5. ISSN: 1535-7163
  1. Abstract:

    We present an analysis of current anticancer compounds that are in phase I, II, or III clinical trials and their structural analogues that have been screened in the National Cancer Institute (NCl) anticancer screening program. Bioactivity profiles, measured across the NCI 60 cell lines, were examined for a correspondence between the type of cancer proposed for clinical testing and selective sensitivity to appropriately matched tumor subpanels in the NCl screen. These results find strongest support for using the NCl anticancer screen to select analogue compounds with selective sensitivity to the leukemia, colon, central nervous system, melanoma, and ovarian panels, but not for renal, prostate, and breast panels. These results are extended to applications of two-dimensional structural features to further refine compound selections based on tumor panel sensitivity obtained from tumor screening results.

    See More

  1. Keywords:

External Sources

  1. View Full Text
  2. DOI: 10.1158/1535-7163.mct-06-0787
  3. View record in Web of Science®
  4. WOS: 000248663000013

Library Notes

  1. No notes added.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel